JP2024521122A5 - - Google Patents
Info
- Publication number
- JP2024521122A5 JP2024521122A5 JP2023572000A JP2023572000A JP2024521122A5 JP 2024521122 A5 JP2024521122 A5 JP 2024521122A5 JP 2023572000 A JP2023572000 A JP 2023572000A JP 2023572000 A JP2023572000 A JP 2023572000A JP 2024521122 A5 JP2024521122 A5 JP 2024521122A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- melanoma
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21382455.0 | 2021-05-19 | ||
| EP21382455 | 2021-05-19 | ||
| PCT/EP2022/063653 WO2022243482A1 (en) | 2021-05-19 | 2022-05-19 | Dosage regimens for ecubectedin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521122A JP2024521122A (ja) | 2024-05-28 |
| JP2024521122A5 true JP2024521122A5 (https=) | 2025-05-27 |
Family
ID=76197383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023572000A Pending JP2024521122A (ja) | 2021-05-19 | 2022-05-19 | エキュベクテディンのための投薬レジメン |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240277705A1 (https=) |
| EP (1) | EP4340841A1 (https=) |
| JP (1) | JP2024521122A (https=) |
| KR (1) | KR20240009437A (https=) |
| CN (1) | CN117295499A (https=) |
| AU (1) | AU2022277799A1 (https=) |
| CA (1) | CA3218171A1 (https=) |
| IL (1) | IL308389A (https=) |
| MX (1) | MX2023013715A (https=) |
| TW (1) | TW202313039A (https=) |
| WO (1) | WO2022243482A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4563149A1 (en) * | 2023-11-30 | 2025-06-04 | Pharma Mar, S.A. | Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers |
| WO2025168075A1 (zh) * | 2024-02-08 | 2025-08-14 | 映恩生物科技(上海)有限公司 | 海鞘素类化合物及其应用 |
| TW202547489A (zh) | 2024-04-30 | 2025-12-16 | 西班牙商瑪製藥股份有限公司 | 化合物ia於包括與阿替利珠單抗的組合療法之癌症的治療中之用途 |
| WO2025228596A1 (en) | 2024-04-30 | 2025-11-06 | Pharma Mar, S.A. | Combination of pm14 and a topoisomerase i inhibitor in the treatment of cancer |
| WO2025228594A1 (en) | 2024-04-30 | 2025-11-06 | Pharma Mar, S.A. | Use of ecubectedin in the treatment of cancers including combination therapy with atezolizumab |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE368461T1 (de) * | 2004-10-29 | 2007-08-15 | Pharma Mar Sa | Zusammensetzungen enthaltend ecteinascidin und einen disaccharide |
| KR102491180B1 (ko) | 2017-04-27 | 2023-01-20 | 파르마 마르 에스.에이. | 항종양 화합물 |
| TWI824043B (zh) * | 2018-10-25 | 2023-12-01 | 西班牙商瑪製藥股份有限公司 | 藥物抗體共軛物 |
-
2022
- 2022-05-19 IL IL308389A patent/IL308389A/en unknown
- 2022-05-19 KR KR1020237042065A patent/KR20240009437A/ko active Pending
- 2022-05-19 EP EP22731103.2A patent/EP4340841A1/en active Pending
- 2022-05-19 MX MX2023013715A patent/MX2023013715A/es unknown
- 2022-05-19 AU AU2022277799A patent/AU2022277799A1/en active Pending
- 2022-05-19 JP JP2023572000A patent/JP2024521122A/ja active Pending
- 2022-05-19 WO PCT/EP2022/063653 patent/WO2022243482A1/en not_active Ceased
- 2022-05-19 TW TW111118548A patent/TW202313039A/zh unknown
- 2022-05-19 CN CN202280034530.0A patent/CN117295499A/zh active Pending
- 2022-05-19 CA CA3218171A patent/CA3218171A1/en active Pending
- 2022-05-19 US US18/560,991 patent/US20240277705A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024521122A5 (https=) | ||
| JP7332293B2 (ja) | バルリチニブおよび抗癌剤を含んでなる併用療法 | |
| CN102089007B (zh) | (a)磷酸肌醇3-激酶抑制剂和(b)ras/raf/mek通路调节剂的组合产品 | |
| JP2024540015A5 (https=) | ||
| JP2019532051A5 (https=) | ||
| JPWO2020130125A5 (https=) | ||
| JP2024532374A5 (https=) | ||
| JP2019521087A5 (https=) | ||
| CN115624550B (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| JP2019516733A5 (https=) | ||
| JP2024505680A5 (https=) | ||
| CN104427986A (zh) | 治疗胃肠道基质瘤的方法 | |
| RU2020142739A (ru) | Ингибиторы mdm2 и их комбинации | |
| KR102708246B1 (ko) | 식도암을 치료하기 위한 퀴놀린 유도체의 용도 및 치료방법, 이의 약제학적 조성물 및 키트 | |
| JP2021523189A (ja) | ビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組成物およびその使用方法 | |
| JP2021523169A (ja) | ビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法 | |
| JP7750884B2 (ja) | ＨＩＦ－２α阻害剤とレンバチニブの組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法 | |
| US11554115B2 (en) | Quinoline derivative for treatment of triple-negative breast cancer | |
| KR20210099022A (ko) | 약제학적 방법 | |
| CN111065395B (zh) | 用于治疗神经内分泌肿瘤的喹啉衍生物 | |
| US20190276439A1 (en) | Method of treating solid tumors | |
| US20230233567A1 (en) | Belvarafenib for use in cancer treatment | |
| CA2457848A1 (en) | Use of 4-pyridylmethylphthalazines for cancer treatment | |
| Mayer et al. | Combination of tivozanib (AV-951) with weekly paclitaxel for metastatic breast cancer: Results of a phase I study | |
| Sorbera et al. | AMG-706 |